Waltham, MA, July 22, 2026 (Reuters) -- Repligen has agreed to acquire BioLife Solutions in a transaction valued at approximately $1.5 billion. The acquisition expands Repligen’s portfolio of bioprocessing technologies and strengthens its capabilities in supporting cell and gene therapy manufacturing. The deal is expected to enhance the company’s offerings for biopharmaceutical customers and support its long-term growth strategy. Read full article here.

Indianapolis, IN, July 20, 2026 (PR Newswire) -- Roche Diagnostics North America has appointed Dan Malarek as president and chief executive officer. Malarek will lead the company’s North American diagnostics business, overseeing commercial strategy, operations, and continued innovation across its portfolio. The leadership appointment is intended to strengthen Roche’s position in the region and support future growth in diagnostic solutions. Read full article here.

Tempe, AZ, June 9, 2026 (PR Newswire) -- GT Medical Technologies has completed an oversubscribed $100 million Series E equity financing to support commercialization of its treatment for patients with operable brain tumors. The proceeds will be used to expand market adoption, scale manufacturing, and advance additional clinical and commercial initiatives. The financing strengthens the company's position as it broadens access to its targeted radiation therapy platform. Read f

Cambridge, MA, July 27, 2026 (Business Wire) -- Sarepta Therapeutics has appointed Michael F. Severino as chief executive officer. Severino will lead the company’s strategic direction as it advances its portfolio of genetic medicines and commercial operations. The leadership appointment is intended to strengthen execution across Sarepta’s pipeline and support its next phase of growth. Read full article here.

Indianapolis and New York, July 16, 2026 (PR Newswire) -- Eli Lilly and Company has agreed to acquire Atai Beckley in a deal worth up to $1.6 billion. The acquisition is intended to strengthen Lilly’s pipeline of therapies for treatment-resistant depression and other mental health disorders by adding novel neuropsychiatric programs. The transaction supports Lilly’s strategy to expand its neuroscience portfolio with innovative treatments for patients with significant unmet n

Stockholm, Sweden, July 7, 2026 (EQT) -- EQT has agreed to acquire the TachoSil biosurgery business from Corza Medical. The transaction will establish TachoSil as an independent company focused on advancing its surgical sealant portfolio and expanding its global market presence. EQT plans to support the business through continued investment in commercial growth, product innovation, and strategic expansion. Read full article here.

San Diego, CA, July 7, 2026 (Globe Newswire) -- ARS Pharmaceuticals has announced a CEO succession plan, with Richard Lowenthal assuming the role of chief executive officer. The leadership transition is designed to support the company’s continued commercial growth and strategic priorities. ARS Pharmaceuticals expects the change to provide continuity as it advances its product portfolio and long-term expansion plans. Read full article here.

Basel, Switzerland, July 6, 2026 (Novartis) -- Novartis has agreed to acquire Myricx Bio in a deal valued at up to $2.9 billion. The acquisition adds Myricx Bio’s next-generation antibody-drug conjugate (ADC) technology, including its novel NMTi payload platform, to strengthen Novartis’ oncology pipeline. The transaction is intended to broaden treatment options for cancer patients and reinforce Novartis’ position in targeted cancer therapies. Read full article here.

New Orleans, LA, July 14, 2026 (PR Newswire) -- ARK Surgical has appointed Joseph B. Labruzzo to its board of directors and as president and chief executive officer of its U.S. operations. Labruzzo will lead the company’s commercial strategy and operational expansion in the United States as ARK Surgical broadens its market presence. The leadership appointment is intended to support the company’s next phase of growth and accelerate adoption of its surgical technologies. Read

Boston, MA, July 12, 2026 (Yahoo Finance) -- Vertex Pharmaceuticals has agreed to acquire Crinetics Pharmaceuticals in a transaction valued at approximately $10 billion. The acquisition strengthens Vertex’s endocrinology pipeline by adding Crinetics’ portfolio of therapies for endocrine disorders, including late-stage programs. The deal supports Vertex’s strategy to diversify its portfolio beyond rare diseases and expand its presence in endocrine medicine. Read full article

San Diego, CA, June 24, 2026 (Business Wire) -- Ollin Biosciences has secured $330 million in an oversubscribed Series B financing round to support global Phase 3 development of OLN324. The funding will be used to advance studies in diabetic macular edema (DME) and wet age-related macular degeneration (AMD), with trials scheduled to begin in the second half of 2026. The financing strengthens the company’s resources as it moves its lead ophthalmology candidate into late-stag

Franklin Lakes, NJ, July 1, 2026 (Drug Delivery Business) -- BD has named Brian Thompson as president of its Pharmacy Automation business. Thompson will lead the division’s strategy and operations as BD seeks to expand its medication management and automation capabilities. The appointment is aimed at supporting growth and advancing innovation across the company’s pharmacy technology portfolio. Read full article here.